Global Sildenafil Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Sildenafil Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Sildenafil (Viagra) is used to treat erectile dysfunction (impotence; inability to get or keep an erection) in men. Sildenafil is in a class of medications called phosphodiesterase (PDE) inhibitors. Sildenafil treats erectile dysfunction by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Sildenafil treats PAH by relaxing the blood vessels in the lungs to allow blood to flow easily.

Market Overview:

The latest research study on the global Sildenafil market finds that the global Sildenafil market reached a value of USD 2188.35 million in 2023. It’s expected that the market will achieve USD 2939.29 million by 2029, exhibiting a CAGR of 5.04% during the forecast period.

Sildenafil Industry Trends

At present, with the reform of the medical and health system entering a new stage and the continuous development of the generic drug market, there are more and more Sildenafil market participants. The market competition of Sildenafil is becoming more and more fierce, which puts great pressure on the development of some Sildenafil enterprises. Under heavy pressure, some Sildenafil companies began to use various methods to improve their competitiveness. If industry companies cannot maintain their leading advantages in technological innovation, new product development, and cost control, the company's products face the risk of a decline in product gross profit margins. To this end, companies in the Sildenafil industry need to further accelerate new product upgrade iterations and achieve product differentiation through R&D innovation and increased R&D investment. For example, from the perspective of product innovation, Sildenafil has continuously strengthened Sildenafil's research on other indications. For example, on February 5, 2020, Pfizer's Revatio® was approved by the National Medical Products Administration (NMPA) of China, becoming the first phosphodiesterase type 5 (PDE-5) inhibitor approved in China for the treatment of pulmonary arterial hypertension. For the treatment of pulmonary hypertension in adults. In addition, Sildenafil has continuously strengthened research on new dosage forms. For example, oral suspensions have the potential to provide a more convenient treatment option for people with swallowing difficulties than tablet formulations. In general, the continuous strengthening of Sildenafil research is one of the trends in the development of the industry.

Market Challenges

The threat of substitute products
At present, there are many kinds of drugs for the treatment of erectile dysfunction on the market, mainly including Sildenafil, Tadalafil, Vardenafil and so on. Among them, Tadalafil takes effect within about half an hour to one hour after oral administration, and the drug effect may last for 36 hours. Tadalafil is a phosphodiesterase type V inhibitor that promotes erections by increasing blood flow to the penis. Compared with Sildenafil, Tadalafil has the advantages of lower dose, longer half-life, longer duration of drug, and is not affected by high-fat diet and alcohol consumption. At present, in clinical use, Tadalafil has better development prospects due to its better clinical performance, and may replace Sildenafil. The threat posed by alternative products such as Tadalafil is one of the challenges facing the development of the industry.

Region Overview:

In 2022, the share of the Sildenafil market in North America stood at 40.06%.

Company Overview:

Viatris is a global healthcare company dedicated to helping people around the world live healthier lives at every stage of life. The company's differentiated product portfolio includes branded, generic and complex generic medicines across multiple therapeutic areas. Viatris better serves customers and patients in more than 165 countries and territories.

TEVA has been committed to developing and producing medicines to help improve people's lives. TEVA strives to be a global leader in generic and specialty medicines, with a portfolio of 3,500 products in virtually every therapeutic area. About 200 million people around the world take Teva medicines every day. In addition to the company's position in generics, the company has significant innovative research and operations that support the company's growing portfolio of specialty and biopharmaceutical products.

Viatris is one of the major players operating in the Sildenafil market, holding a share of 29.03% in 2023.

Segmentation Overview:

By type, 50mg/Tablets segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Retail Pharmacies segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Sildenafil market covered in Chapter 3:

Centurion Laboritories
TEVA
Aurobindo
Baiyunshan Pharma
Bristol Laboratories
Jiangsu Yabang Epson Pharmaceutical Co., Ltd
Viatris

In Chapter 4 and Chapter 14.2, on the basis of types, the Sildenafil market from 2019 to 2030 is primarily split into:

50mg/Tablets
100mg/Tablets
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Sildenafil market from 2019 to 2030 covers:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)